Medicare AdvantageCoverageMedium impact
MA08.016h, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
Independence Blue Cross·Pulmonology, Cardiology, Critical Care·Pharmacy
Effective date
Apr 21, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated medical necessity criteria for treating pulmonary artery hypertension with intravenous, subcutaneous, and inhaled pharmacologic agents. This affects coverage requirements and approval processes for PAH medications administered through these routes.
Action Required
By April 21, 2025: Billing team must review updated medical necessity criteria for pulmonary artery hypertension treatments using IV, subcutaneous, and inhaled medications. Update prior authorization documentation requirements in billing system. Notify providers treating PAH patients to ensure documentation meets new criteria to avoid claim denials.